Personalis (PSNL) is a stock which I have watched with great interest since it went public earlier this year, yet in August I was forced to conclude that the potential growth champion has much to prove. That observation has proven to be correct with shares down to $10 at the moment of writing following disappointing (commercial) sales, although the low valuation and conference call give me enough confidence to initiate a small speculative long position.
The Business - Personalised Health
Personalis describes itself as a cancer genomics business which aims to change the